BioSpace News Archive

Certara, Inc., a global leader in biosimulation, reported its financial results for the first quarter of fiscal year 2024.

Globus Medical, Inc., a leading musculoskeletal solutions company, announced its financial results for the quarter ended March 31, 2024.

CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US and Canada) for CytomX’s first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Cryoport, Inc. (NASDAQ: CYRX) (Cryoport), a global leader in supply chain solutions for the life sciences, today announced financial results for the three months ended March 31 (Q1), 2024.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the BofA Securities 2024 Health Care Conference at 11:20 a.m. Pacific Time (2:20 p.m. Eastern Time) on Tuesday May 14, 2024 in Las Vegas.

Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on July 26, 2024 to holders of record on June 28, 2024.

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2024.

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2024.

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024.